Feb 26- Cosmetics maker Revlon Inc Chief Executive Lorenzo Delpani is stepping down for personal reasons, more than a month after its controlling shareholder and Chairman Ron Perelman announced plans to seek strategic options for the company. Revlon, once a top name in the world of beauty products and endorsed by supermodel Cindy Crawford for more than a...
Feb 26- Cosmetics maker Revlon Inc said Chief Executive Lorenzo Delpani would step down for personal reasons. Revlon sales rose 4.2 percent to $521.9 million in the fourth quarter ended Dec. 31, helped by demand for its Revlon and SinfulColors cosmetics in the United States. Revlon shares closed at $31.17 on Thursday on the New York Stock Exchange.
Feb 26- Cosmetics maker Revlon Inc said on Friday Chief Executive Lorenzo Delpani would step down for personal reasons.
Fine jewelry is the original wearable investment and unlike the Apple Watch doesn't have to be upgraded with new technology every few years.
The Apollo appears to be in a good position to reclaim its place in pop culture, entertaining over 100,000 people a year with a $13 million budget.
Adrian Barrie Smith, who recruits housekeeping staff for the wealthy, has sued several well-known Wall Street financiers and even the comedian Jerry Seinfeld.
The SEC says Revlon has agreed to pay a $850,000 fine for misleading shareholders about details of a "going-private" transaction.
There's a battle underway in the surf-side playground of the rich and famous, reports CNBC's Robert Frank.
"I was best friends with my partners for 25 years. I mourn the loss of that friendship," Don Drapkin, the head of Casablanca Capital, said of his former business partner at MacAndrews & Forbes, financier Ron Perelman.
The chairman of the House Oversight and Government Reform Committee told CNBC that he wants to know whether political considerations drove the government’s decision to steer a potentially multibillion-dollar contract to a company in which financier Ron Perelman's investment firm has a significant stake.
Financier Ron Perelman’s entry into the smallpox antiviral medicine business has led to a congressional investigation, CNBC has learned.